{"id":5125,"date":"2024-03-08T14:48:18","date_gmt":"2024-03-08T17:48:18","guid":{"rendered":"https:\/\/artica.capital\/clairfield-pilulas\/como-a-novo-nordisk-tornou-se-a-empresa-mais-valiosa-da-europa\/"},"modified":"2026-09-29T15:18:43","modified_gmt":"2026-09-29T18:18:43","slug":"como-a-novo-nordisk-tornou-se-a-empresa-mais-valiosa-da-europa","status":"publish","type":"pilulas","link":"https:\/\/artica.capital\/en\/clairfield-pilulas\/como-a-novo-nordisk-tornou-se-a-empresa-mais-valiosa-da-europa\/","title":{"rendered":"How did Novo Nordisk become the most valuable company in Europe?"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">A farmac\u00eautica Novo Nordisk tornou-se a empresa listada mais valiosa da Europa, ultrapassando o conglomerado de luxo LMVH. A fabricante do Ozempic e do Wegovy apresentou ganhos e resultados recordes devido aos seus medicamentos altamente eficazes para diabetes e perda de peso.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Al\u00e9m disso, as a\u00e7\u00f5es da empresa passaram por forte valoriza\u00e7\u00e3o nos \u00faltimos meses, principalmente relacionada aos investimentos que a empresa realizou buscando aumentar sua capacidade produtiva. O mais recente destes, foi a compra da Catalent, que j\u00e1 era a principal fornecedora de insumos dos produtos para perda de peso, por USD 11,5 bilh\u00f5es.<\/p>\n\n\n\n<!-- pilula-html v1 -->\n<style>\n.pil{--navy:#2d3a51;--blue:#4f6388;--light:#8599b9;--pale:#e8ebf1;--card:#d3d9e3;--red:#c0272d;--txt:#333;font-family:\"Merriweather Sans\",sans-serif;color:var(--txt);margin-top:40px}\n.pil *{box-sizing:border-box}\n.pil img{max-width:100%;height:auto;display:block}\n.pil-sec{margin:0 0 56px}\n.pil-sec h2{background:var(--navy);color:#fff;font-size:19px;line-height:1.35;font-weight:700;padding:16px 20px;border-radius:0 0 28px 0;margin:0 0 20px;text-wrap:balance}\n.pil-sub{font-size:14px;font-weight:700;color:var(--navy);border-bottom:2px solid var(--navy);padding-bottom:6px;margin:0 0 16px;display:flex;justify-content:space-between;gap:12px;align-items:flex-end}\n.pil-tag{color:var(--red);border-top:2px solid var(--red);border-bottom:2px solid var(--red);font-size:12px;padding:2px 8px;white-space:nowrap}\n.pil-unit{font-size:12px;font-style:italic;color:#999;font-weight:700}\n.pil-src{font-size:11px;color:#777;margin-top:14px;line-height:1.5}\n.pil-p{font-size:14px;line-height:1.6;margin:0 0 12px}\n.pil-note{display:flex;gap:12px;align-items:center;background:var(--pale);border:1.5px dashed var(--navy);border-radius:10px;padding:12px 16px;font-size:14px;line-height:1.55;margin-top:18px}\n.pil-note::before{content:\"\";flex:none;width:26px;height:26px;border-radius:50%;background:var(--navy) url(\"data:image\/svg+xml,%3Csvg xmlns='http:\/\/www.w3.org\/2000\/svg' viewBox='0 0 24 24' fill='none' stroke='white' stroke-width='1.8' stroke-linecap='round'%3E%3Cpath d='M9 18h6M10 21h4M12 3a6 6 0 0 0-3.5 10.9c.6.5 1 1.2 1 2.1h5c0-.9.4-1.6 1-2.1A6 6 0 0 0 12 3z'\/%3E%3C\/svg%3E\") center\/16px no-repeat}\n.pil-note.solid{border-style:solid;background:#fff;box-shadow:0 2px 6px rgba(0,0,0,.12)}\n.pil-note.solid::before{display:none}\n.pil-grid2{display:grid;grid-template-columns:1fr 1fr;gap:24px}\n.pil-grid2.wide-left{grid-template-columns:1.75fr 1fr}\n.pil-grid2.wide-right{grid-template-columns:1fr 1.75fr}\n.pil-grid3{display:grid;grid-template-columns:repeat(3,1fr);gap:20px}\n.pil-grid4{display:grid;grid-template-columns:repeat(4,1fr);gap:16px}\n.pil-grid5{display:grid;grid-template-columns:repeat(5,1fr);gap:12px}\n.pil-grid2>*,.pil-grid3>*,.pil-grid4>*,.pil-grid5>*{min-width:0}\n.pil-legend{font-size:12px;display:flex;gap:14px;justify-content:flex-end;flex-wrap:wrap;margin-bottom:6px}\n.pil-legend span{display:inline-flex;align-items:center;gap:6px}\n.pil-legend i{width:14px;height:10px;display:inline-block}\n\/* grafico de colunas: .pil-bars > div[style=height:%] > span (valor); .pil-years > span *\/\n.pil-bars{display:flex;align-items:flex-end;gap:2.2%;height:240px;border-bottom:1.5px solid #333;padding:22px 1% 0}\n.pil-bars>div{flex:1;background:var(--light);position:relative;min-height:1px}\n.pil-bars>div.e{background:var(--blue)}\n.pil-bars>div.cur{background:var(--navy)}\n.pil-bars>div>span{position:absolute;top:-19px;left:50%;transform:translateX(-50%);font-size:12px;white-space:nowrap}\n.pil-years{display:flex;gap:2.2%;padding:4px 1% 0;font-size:11px;text-align:center}\n.pil-years span{flex:1}\n.pil-cagr{text-align:center;font-size:12px;font-weight:700}\n.pil-cagr span{display:inline-block;border:1.5px solid #222;border-radius:50%;padding:2px 8px;margin-top:4px}\n\/* barras horizontais: .pil-hbars > .r > (b nome) (.bar > i[style=width:%]) (em valor) *\/\n.pil-hbars{display:grid;gap:8px;font-size:13px}\n.pil-hbars .r{display:grid;grid-template-columns:minmax(90px,30%) 1fr auto;gap:10px;align-items:center}\n.pil-hbars .bar{background:var(--pale);height:18px}\n.pil-hbars .bar i{display:block;height:100%;background:var(--blue)}\n.pil-hbars em{font-style:normal;font-weight:700;color:var(--navy);min-width:48px;text-align:right}\n\/* cartoes de numeros *\/\n.pil-box{border:2px solid var(--navy);border-radius:0 0 10px 10px;background:#fff}\n.pil-box>h3{margin:0;background:var(--navy);color:#fff;font-size:14px;text-align:center;padding:8px}\n.pil-stat{text-align:center;padding:16px 14px;font-size:13px;line-height:1.45}\n.pil-stat strong{display:block;font-size:40px;color:var(--blue);font-weight:800;line-height:1.1}\n.pil-stat strong small{font-size:22px}\n.pil-stat em{font-style:normal;color:var(--blue);font-weight:700}\n.pil-card{background:#fff;border-radius:12px;box-shadow:0 1px 5px rgba(0,0,0,.14);padding:14px 16px;font-size:13px;line-height:1.5}\n.pil-card h3{font-size:15px;color:var(--navy);margin:0 0 8px}\n.pil-card.tint{background:var(--card);box-shadow:none}\n\/* listas e fatos *\/\n.pil-list{margin:0;padding-left:18px;font-size:14px;line-height:1.6}\n.pil-list li{margin-bottom:6px}\n.pil-fact{font-size:14px;line-height:1.5;padding-left:14px;border-left:3px solid var(--light)}\n.pil-fact.dark{border-color:var(--navy)}\n.pil-fact b{color:var(--navy)}\n.pil-fact big{font-size:20px;font-weight:800;color:var(--navy)}\n.pil-hl{color:var(--blue);font-weight:700}\n\/* tabela *\/\n.pil-tw{overflow-x:auto}\n.pil-table{width:100%;border-collapse:collapse;font-size:13px}\n.pil-table th{background:var(--navy);color:#fff;text-align:left;padding:8px 10px;font-weight:700}\n.pil-table td{padding:7px 10px;border-bottom:1px solid #d8dce4;vertical-align:top}\n.pil-table tr:nth-child(even) td{background:#f5f6f9}\n.pil-table .n{text-align:right;font-variant-numeric:tabular-nums;white-space:nowrap}\n\/* linha do tempo *\/\n.pil-time{display:grid;gap:14px;border-left:2px dashed var(--light);padding-left:18px;margin-left:6px}\n.pil-time>div{position:relative;font-size:14px;line-height:1.5}\n.pil-time>div::before{content:\"\";position:absolute;left:-25px;top:5px;width:12px;height:12px;border-radius:50%;background:var(--navy)}\n.pil-time b.y{display:block;color:var(--light);font-size:16px;font-weight:800}\n\/* figuras (recortes do slide) *\/\n.pil-fig{margin:0}\n.pil-fig figcaption{text-align:center;font-weight:800;color:var(--light);font-size:16px;margin-top:4px}\n.pil-brand{background:var(--card);border-radius:14px;overflow:hidden}\n.pil-brand p{margin:0;text-align:center;font-size:20px;font-weight:800;font-style:italic;color:var(--navy);padding:10px 0 12px}\n@media (max-width:700px){\n  .pil-grid2,.pil-grid2.wide-left,.pil-grid2.wide-right{grid-template-columns:1fr}\n  .pil-grid3,.pil-grid4,.pil-grid5{grid-template-columns:1fr 1fr}\n  .pil-sec h2{font-size:17px}\n  .pil-bars{height:180px}\n  .pil-bars>div>span{font-size:10px}\n  .pil-years{font-size:9px}\n}\n@media (max-width:480px){\n  .pil-bars{gap:1.2%}\n  .pil-years{gap:1.2%;font-size:8px}\n  .pil-bars>div>span{font-size:8px;letter-spacing:-.3px}\n  .pil-bars:has(>div:nth-child(13))>div>span{writing-mode:vertical-rl;transform:translateX(-50%) rotate(180deg);top:auto;bottom:100%;padding-bottom:2px}\n  .pil-years:has(>span:nth-child(13)) span{writing-mode:vertical-rl;transform:rotate(180deg);margin:0 auto}\n}\n<\/style>\n<div class=\"pil\">\n\n<section class=\"pil-sec\">\n  <h2>A a\u00e7\u00e3o da farmac\u00eautica apresentou crescimento superior a 70% no \u00faltimo ano, acompanhado por m\u00faltiplos investimentos, inclusive aquisi\u00e7\u00f5es<\/h2>\n  <div class=\"pil-grid2 wide-left\">\n    <div>\n      <div class=\"pil-sub\"><span>Evolu\u00e7\u00e3o do pre\u00e7o das a\u00e7\u00f5es da Novo Nordisk (NOVO-B) listada na Nasdaq Copenhagen<\/span><\/div>\n      <img decoding=\"async\" src=\"https:\/\/artica.capital\/wp-content\/uploads\/2026\/09\/5125-grafico.png\" alt=\"Gr\u00e1fico de linha do pre\u00e7o da a\u00e7\u00e3o NOVO-B em coroas dinamarquesas, de jan\/23 a mar\/24: sobe de cerca de 490 DKK para mais de 830 DKK, com os marcadores de investimentos A (jun\/23), B (ago\/23), C (nov\/23), D (dez\/23), E (fev\/24) e F (mar\/24)\" loading=\"lazy\">\n    <\/div>\n    <div>\n      <div class=\"pil-sub\"><span>Investimentos<\/span><\/div>\n      <div style=\"display:grid;gap:12px\">\n        <div style=\"display:grid;grid-template-columns:30px 1fr;gap:12px;align-items:center\"><b style=\"width:30px;height:30px;border-radius:50%;background:#111;color:#fff;display:flex;align-items:center;justify-content:center\">A<\/b><span>Expans\u00e3o de unidades fabris na Dinamarca<\/span><\/div>\n        <div style=\"display:grid;grid-template-columns:30px 1fr;gap:12px;align-items:center\"><b style=\"width:30px;height:30px;border-radius:50%;background:#111;color:#fff;display:flex;align-items:center;justify-content:center\">B<\/b><span>Compra da Inversago Pharma<\/span><\/div>\n        <div style=\"display:grid;grid-template-columns:30px 1fr;gap:12px;align-items:center\"><b style=\"width:30px;height:30px;border-radius:50%;background:#111;color:#fff;display:flex;align-items:center;justify-content:center\">C<\/b><span>Compra da divis\u00e3o de ocedurenone da KBP Biosciences<\/span><\/div>\n        <div style=\"display:grid;grid-template-columns:30px 1fr;gap:12px;align-items:center\"><b style=\"width:30px;height:30px;border-radius:50%;background:#111;color:#fff;display:flex;align-items:center;justify-content:center\">D<\/b><span>Expans\u00e3o das unidades da Fran\u00e7a<\/span><\/div>\n        <div style=\"display:grid;grid-template-columns:30px 1fr;gap:12px;align-items:center\"><b style=\"width:30px;height:30px;border-radius:50%;background:#111;color:#fff;display:flex;align-items:center;justify-content:center\">E<\/b><span>Investimento na Omega Therapeutics e Cellarity<\/span><\/div>\n        <div style=\"display:grid;grid-template-columns:30px 1fr;gap:12px;align-items:center\"><b style=\"width:30px;height:30px;border-radius:50%;background:#111;color:#fff;display:flex;align-items:center;justify-content:center\">F<\/b><span>Adquiriu a Catalent<\/span><\/div>\n      <\/div>\n    <\/div>\n  <\/div>\n  <div class=\"pil-src\">Fonte: Yahoo Finance, Investor Relation\/Press release Novo Nordisk<\/div>\n<\/section>\n\n<section class=\"pil-sec\">\n  <h2>Em fevereiro de 2024, a Novo Nordisk anunciou a aquisi\u00e7\u00e3o da Catalent por USD 11,5 bilh\u00f5es (~R$ 57,3 bilh\u00f5es<sup>(1)<\/sup>)<\/h2>\n  <div class=\"pil-grid2\">\n    <div class=\"pil-card tint\" style=\"border-radius:28px;display:grid;gap:16px\">\n      <img decoding=\"async\" src=\"https:\/\/artica.capital\/wp-content\/uploads\/2026\/09\/5125-catalent.png\" alt=\"Logo da Catalent\" loading=\"lazy\" style=\"max-width:240px;margin:0 auto;mix-blend-mode:multiply\">\n      <div style=\"display:grid;grid-template-columns:48px 1fr;gap:12px;align-items:center\"><img decoding=\"async\" src=\"https:\/\/artica.capital\/wp-content\/uploads\/2026\/09\/5125-ic-lab.png\" alt=\"\u00cdcone de microsc\u00f3pio\" loading=\"lazy\" style=\"mix-blend-mode:multiply\"><span style=\"font-size:14px\">Desenvolvimento e fabrica\u00e7\u00e3o de medicamentos e produtos biol\u00f3gicos<\/span><\/div>\n      <div style=\"display:grid;grid-template-columns:48px 1fr;gap:12px;align-items:center\"><img decoding=\"async\" src=\"https:\/\/artica.capital\/wp-content\/uploads\/2026\/09\/5125-ic-globo.png\" alt=\"\u00cdcone de globo\" loading=\"lazy\" style=\"mix-blend-mode:multiply\"><span style=\"font-size:14px\">Presen\u00e7a na \u00c1sia, Europa, Am\u00e9rica Latina e Am\u00e9rica do Norte<\/span><\/div>\n      <div style=\"display:grid;grid-template-columns:48px 1fr;gap:12px;align-items:center\"><img decoding=\"async\" src=\"https:\/\/artica.capital\/wp-content\/uploads\/2026\/09\/5125-ic-moedas.png\" alt=\"\u00cdcone de moedas\" loading=\"lazy\" style=\"mix-blend-mode:multiply\"><span style=\"font-size:14px\">Receita de 2023 de USD 4,3 bilh\u00f5es, com margem EBITDA ajustada de ~17%<\/span><\/div>\n    <\/div>\n    <div>\n      <div class=\"pil-sub\"><span>Racional da aquisi\u00e7\u00e3o<\/span><\/div>\n      <div class=\"pil-time\">\n        <div>A Novo Nordisk buscava aumentar sua capacidade produtiva e estoque<\/div>\n        <div>Adquiriu 3 unidades de fabrica\u00e7\u00e3o e envase da Catalent na It\u00e1lia, B\u00e9lgica e EUA<\/div>\n        <div>Planos de expans\u00e3o da capacidade produtiva estimados em ~USD 6,0 bilh\u00f5es<\/div>\n      <\/div>\n      <div class=\"pil-note solid\"><span><b style=\"font-size:22px;color:var(--navy)\">+<\/b> Em busca de manter-se na lideran\u00e7a do mercado e desenvolvimento da ci\u00eancia, a empresa possui <b>~USD 200,0 milh\u00f5es anuais para investimentos<\/b><\/span><\/div>\n    <\/div>\n  <\/div>\n  <div class=\"pil-src\">(1) Considera taxa de c\u00e2mbio BRL\/USD = 4,97<br>Fonte: Sifted (Financial Times), Reuters, Yahoo Finance, Catalent RI.<\/div>\n<\/section>\n\n<\/div>\n\n","protected":false},"excerpt":{"rendered":"<p>Pharmaceutical company Novo Nordisk has become Europe&#039;s most valuable listed company, surpassing luxury conglomerate LMVH. The maker of Ozempic and Wegovy reported record earnings and results thanks to its highly effective diabetes and weight-loss medications.<\/p>","protected":false},"author":1,"featured_media":5122,"template":"","meta":[],"class_list":["post-5125","pilulas","type-pilulas","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/artica.capital\/en\/wp-json\/wp\/v2\/pilulas\/5125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/artica.capital\/en\/wp-json\/wp\/v2\/pilulas"}],"about":[{"href":"https:\/\/artica.capital\/en\/wp-json\/wp\/v2\/types\/pilulas"}],"author":[{"embeddable":true,"href":"https:\/\/artica.capital\/en\/wp-json\/wp\/v2\/users\/1"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/artica.capital\/en\/wp-json\/wp\/v2\/media\/5122"}],"wp:attachment":[{"href":"https:\/\/artica.capital\/en\/wp-json\/wp\/v2\/media?parent=5125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}